Pulmonary Arterial Hypertension Therapeutics Reviewed by Global Data23 Apr 2012 • by Natalie Aster
The global PAH therapeutics market is estimated to be worth $3.1 billion in 2020. It is forecast to show a negative CAGR of 0.6% during 2011 to 2020. This trend is on the account of significant number of patent expiries or loss of ODE in the forecast period. In 2020, the three leading drugs in the major PAH therapeutics market will be riociguat, macitentan and Tyvaso with estimated sales of $700.5m, $437.7m and $421.3m, respectively.
According to the report “Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020” by GlobalData, the current competition in the global PAH therapeutics market is strong in spite of low patient numbers; this is due to the high competitive intensity in the PAH therapeutics market. There are three main classes of drugs present in the market: Endothelin Receptor Antagonist (ERA), prostacyclins, and Phosphodiesterase-5 (PDE-5) inhibitors. All of these drugs have demonstrated satisfactory efficacy.Drugs from different classes is also used as combination therapies. Therefore, there is strong competition for a me-too drug in the global PAH therapeutics. However simultaneously there is a need for a drug which improves the disease pathogenesis.
Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
Published: March, 2012
Price: US$ 6.995,00
The PAH therapeutics market has high unmet need in terms of efficacy and safety. Based on the safety, efficacy and ACOT assessment, the unmet need in the PAH therapeutics market was found to be high. This infers that despite the availability of a significant number of treatment options, there is a need for the new products with improved safety and efficacy.
There is a need in the PAH therapeutics market for products which can reverse pulmonary vascular remodeling, further improve survival rates, and can delay disease progression.
More information can be found in the report “Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020” by GlobalData.
To order the report or ask for sample pages contact firstname.lastname@example.org